Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis

Basit Öğe Kaydı
dc.contributor.authorOcak, S.
dc.contributor.authorDuran, N.
dc.contributor.authorKaya, H.
dc.contributor.authorEmir, I.
dc.date.accessioned2024-09-18T20:26:32Z
dc.date.available2024-09-18T20:26:32Z
dc.date.issued2006
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractType 2 diabetes mellitus (DM) has emerged as the commonest cause of end-stage renal disease. Haemodialysis (HD) treatment constitutes a high-risk environment for the transmission of hepatitis C virus (HCV). The aim of this study was to establish a potential relationship between type 2 DM and HCV infection in HD patients. Of the 267 HD patients, 67 (25.1%) had type 2 DM and 200 (74.9%) were with diverse aetiology for end-stage renal disease. The serum markers of HCV infection were tested by a second-generation enzyme-linked immunosorbent assay test for, antibodies and by qualitative reverse-transcription polymerase chain reaction technique for viral RNA. The overall prevalence of anti-HCV antibodies and HCV RNA was found to be 12.7% (34/267) and 10.1% (27/267), respectively. Patients with type 2 DM were found to have a higher HCV prevalence compared with non-diabetic patients [20.8% (14/67) vs. 10% (20/200)] (p < 0.05). The mean period on dialysis of anti-HCV-positive patients with type 2 DM was shorter than that observed for anti-HCV-positive non-diabetic patients (43.9 +/- 9.8 months vs. 59.7 +/- 28.4 months) (p < 0.05). This study has shown that although the period on dialysis of diabetic patients are shorter than non-diabetic patients, the prevalence of HCV in HD patients with type 2 DM is higher than that detected in non-diabetic HD patients.en_US
dc.identifier.doi10.1111/j.1368-5031.2006.00738.x
dc.identifier.endpage674en_US
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue6en_US
dc.identifier.pmid16805751en_US
dc.identifier.scopus2-s2.0-33744517113en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage670en_US
dc.identifier.urihttps://doi.org/10.1111/j.1368-5031.2006.00738.x
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10379
dc.identifier.volume60en_US
dc.identifier.wosWOS:000238391400011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthaemodialysisen_US
dc.subjectdiabetes mellitusen_US
dc.subjectHCVen_US
dc.subjectantibodyen_US
dc.subjectELISAen_US
dc.titleSeroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
81.73 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu